US20200223876A1 - Biosensor - Google Patents
Biosensor Download PDFInfo
- Publication number
- US20200223876A1 US20200223876A1 US16/822,710 US202016822710A US2020223876A1 US 20200223876 A1 US20200223876 A1 US 20200223876A1 US 202016822710 A US202016822710 A US 202016822710A US 2020223876 A1 US2020223876 A1 US 2020223876A1
- Authority
- US
- United States
- Prior art keywords
- biosensor according
- coil
- coiled wire
- biocompatible
- bioreceptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920005989 resin Polymers 0.000 claims abstract description 12
- 239000011347 resin Substances 0.000 claims abstract description 12
- 230000000694 effects Effects 0.000 claims abstract description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 49
- 239000008103 glucose Substances 0.000 claims description 49
- 235000019420 glucose oxidase Nutrition 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 15
- 239000000560 biocompatible material Substances 0.000 claims description 14
- 229920001577 copolymer Polymers 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 229940088598 enzyme Drugs 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 108010015776 Glucose oxidase Proteins 0.000 claims description 7
- 239000004366 Glucose oxidase Substances 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 229940116332 glucose oxidase Drugs 0.000 claims description 7
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 239000000178 monomer Substances 0.000 claims description 6
- 125000006850 spacer group Chemical group 0.000 claims description 6
- 102000004316 Oxidoreductases Human genes 0.000 claims description 5
- 108090000854 Oxidoreductases Proteins 0.000 claims description 5
- 229910021607 Silver chloride Inorganic materials 0.000 claims description 5
- -1 polyethylene Polymers 0.000 claims description 5
- 229910052709 silver Inorganic materials 0.000 claims description 5
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 4
- 239000004332 silver Substances 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 229920000570 polyether Polymers 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000004812 Fluorinated ethylene propylene Substances 0.000 claims description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 2
- 239000002033 PVDF binder Substances 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 229920002614 Polyether block amide Polymers 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 239000004642 Polyimide Substances 0.000 claims description 2
- 239000004734 Polyphenylene sulfide Substances 0.000 claims description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 2
- 108010042687 Pyruvate Oxidase Proteins 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 150000005215 alkyl ethers Chemical class 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 claims description 2
- 229920001903 high density polyethylene Polymers 0.000 claims description 2
- 239000004700 high-density polyethylene Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 229920001684 low density polyethylene Polymers 0.000 claims description 2
- 239000004702 low-density polyethylene Substances 0.000 claims description 2
- 229920009441 perflouroethylene propylene Polymers 0.000 claims description 2
- 229920003055 poly(ester-imide) Polymers 0.000 claims description 2
- 229920001643 poly(ether ketone) Polymers 0.000 claims description 2
- 229920000052 poly(p-xylylene) Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920001721 polyimide Polymers 0.000 claims description 2
- 229920000069 polyphenylene sulfide Polymers 0.000 claims description 2
- 229940058401 polytetrafluoroethylene Drugs 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229920001940 conductive polymer Polymers 0.000 claims 1
- 229920001519 homopolymer Polymers 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 36
- 239000008280 blood Substances 0.000 description 31
- 210000004369 blood Anatomy 0.000 description 31
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 238000012360 testing method Methods 0.000 description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 229910052697 platinum Inorganic materials 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 229920001661 Chitosan Polymers 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 229910001220 stainless steel Inorganic materials 0.000 description 9
- GKWLILHTTGWKLQ-UHFFFAOYSA-N 2,3-dihydrothieno[3,4-b][1,4]dioxine Chemical class O1CCOC2=CSC=C21 GKWLILHTTGWKLQ-UHFFFAOYSA-N 0.000 description 8
- 238000011088 calibration curve Methods 0.000 description 8
- 239000010935 stainless steel Substances 0.000 description 8
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 7
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 7
- 229920000557 Nafion® Polymers 0.000 description 7
- 229920001609 Poly(3,4-ethylenedioxythiophene) Polymers 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 229910001868 water Inorganic materials 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000000017 hydrogel Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 4
- 210000000744 eyelid Anatomy 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000003618 dip coating Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000005672 electromagnetic field Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229920000083 poly(allylamine) Polymers 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920002491 Diethylaminoethyl-dextran Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 0 [2*]C1=C[1*]C=C1[3*] Chemical compound [2*]C1=C[1*]C=C1[3*] 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000004082 amperometric method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 238000007705 chemical test Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- HMLSBRLVTDLLOI-UHFFFAOYSA-N 1-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)C(C)OC(=O)C(C)=C HMLSBRLVTDLLOI-UHFFFAOYSA-N 0.000 description 1
- NGDQARFGFFQENN-UHFFFAOYSA-N 2,3,4,5-tetrahydrothieno[3,4-b][1,4]dioxocine Chemical compound O1CCCCOC2=CSC=C21 NGDQARFGFFQENN-UHFFFAOYSA-N 0.000 description 1
- QWOJHHARDZEQSU-UHFFFAOYSA-N 3,4-dihydro-2h-thieno[3,4-b][1,4]dioxepine;2,3-dihydrothieno[3,4-b][1,4]dioxine Chemical compound O1CCOC2=CSC=C21.O1CCCOC2=CSC=C21 QWOJHHARDZEQSU-UHFFFAOYSA-N 0.000 description 1
- MXLYDTCSOHXFFA-UHFFFAOYSA-N 3-methyl-2,3-dihydrothieno[3,4-b][1,4]dioxine Chemical compound O1C(C)COC2=CSC=C21 MXLYDTCSOHXFFA-UHFFFAOYSA-N 0.000 description 1
- 241001552669 Adonis annua Species 0.000 description 1
- OAHXMKWJQOMLMP-UHFFFAOYSA-N C=1SC=C2OCC3=C(COC21)C=CC=C3.O3C=2C(OCC(C3)O)=CSC2.O2C=3C(OCC(C2)CO)=CSC3.CC3COC=2C(OC3)=CSC2 Chemical compound C=1SC=C2OCC3=C(COC21)C=CC=C3.O3C=2C(OCC(C3)O)=CSC2.O2C=3C(OCC(C2)CO)=CSC3.CC3COC=2C(OC3)=CSC2 OAHXMKWJQOMLMP-UHFFFAOYSA-N 0.000 description 1
- WJBTYJWMVKTXCH-UHFFFAOYSA-N CC1COC=2C(O1)=CSC2.O2C=1C(OCC2O)=CSC1.CC1C(C(C(OC=2C(O1)=CSC2)C)C)C Chemical compound CC1COC=2C(O1)=CSC2.O2C=1C(OCC2O)=CSC1.CC1C(C(C(OC=2C(O1)=CSC2)C)C)C WJBTYJWMVKTXCH-UHFFFAOYSA-N 0.000 description 1
- XQUQWGURSUQGNF-UHFFFAOYSA-N COCC1(COC=2C(OC1)=CSC2)COC.CC2(COC=1C(OC2)=CSC1)C.CC1C(OC=2C(O1)=CSC2)C Chemical compound COCC1(COC=2C(OC1)=CSC2)COC.CC2(COC=1C(OC2)=CSC1)C.CC1C(OC=2C(O1)=CSC2)C XQUQWGURSUQGNF-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010074303 Dihydrobenzophenanthridine oxidase Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010090758 L-gulonolactone oxidase Proteins 0.000 description 1
- 108010029541 Laccase Proteins 0.000 description 1
- 102000016261 Long-Acting Insulin Human genes 0.000 description 1
- 108010092217 Long-Acting Insulin Proteins 0.000 description 1
- 229940100066 Long-acting insulin Drugs 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- LIAWBRHJFNUDEU-UHFFFAOYSA-M O1C=2C(OCC1COCCCCS(=O)(=O)[O-])=CSC2.[Na+].C2(=CC=CC=C2)C2COC=1C(O2)=CSC1.O1C=2C(OCC1CO)=CSC2 Chemical compound O1C=2C(OCC1COCCCCS(=O)(=O)[O-])=CSC2.[Na+].C2(=CC=CC=C2)C2COC=1C(O2)=CSC1.O1C=2C(OCC1CO)=CSC2 LIAWBRHJFNUDEU-UHFFFAOYSA-M 0.000 description 1
- NXGQWVKSKOYDIA-UHFFFAOYSA-N O=O.OO Chemical compound O=O.OO NXGQWVKSKOYDIA-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020001991 Protoporphyrinogen Oxidase Proteins 0.000 description 1
- 102000005135 Protoporphyrinogen oxidase Human genes 0.000 description 1
- 108010060059 Sarcosine Oxidase Proteins 0.000 description 1
- 102000008118 Sarcosine oxidase Human genes 0.000 description 1
- 108010027912 Sulfite Oxidase Proteins 0.000 description 1
- 102000043440 Sulfite oxidase Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 108030001000 Thiamine oxidases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000005513 bias potential Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
- KBLWLMPSVYBVDK-UHFFFAOYSA-N cyclohexyl prop-2-enoate Chemical compound C=CC(=O)OC1CCCCC1 KBLWLMPSVYBVDK-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007772 electrode material Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940005267 urate oxidase Drugs 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2224—Compounds having one or more tin-oxygen linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
- A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G19/00—Compounds of tin
- C01G19/02—Oxides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K9/00—Use of pretreated ingredients
- C08K9/04—Ingredients treated with organic substances
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09C—TREATMENT OF INORGANIC MATERIALS, OTHER THAN FIBROUS FILLERS, TO ENHANCE THEIR PIGMENTING OR FILLING PROPERTIES ; PREPARATION OF CARBON BLACK ; PREPARATION OF INORGANIC MATERIALS WHICH ARE NO SINGLE CHEMICAL COMPOUNDS AND WHICH ARE MAINLY USED AS PIGMENTS OR FILLERS
- C09C1/00—Treatment of specific inorganic materials other than fibrous fillers; Preparation of carbon black
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
- G01N27/3272—Test elements therefor, i.e. disposable laminated substrates with electrodes, reagent and channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/50—Solid solutions
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49002—Electrical device making
- Y10T29/49117—Conductor or circuit manufacturing
Definitions
- the invention relates to a biosensor and to a process for the preparation thereof.
- the invention also relates to a medical device comprising the biosensor.
- Blood glucose monitoring is a way of testing the concentration of glucose in the blood (glycemia). It is important in the care of diabetes mellitus.
- a blood glucose test is generally performed by piercing the skin (typically, on the finger tip) to draw blood, then placing the blood on a chemically active disposable strip which indicates the result either by changing colour, or changing an electrical characteristic, the latter being measured by an electronic meter.
- Type 2 diabetes Many people with Type 2 diabetes use an oral medication to combat their insulin resistance, and test their blood glucose before and after breakfast to assess the effectiveness of their dosage. Diabetics who use insulin (all Type 1 diabetes patients and many Type 2 diabetes patients) usually test their blood sugar more often, such as 3 to 10 times per day, both to assess the effectiveness of their prior insulin dose and to help determining the time of their next insulin dose.
- Chemical test strips are a medium cost method for monitoring blood glucose. A fairly large drop of blood, usually taken from the fingertip, is placed on a chemically prepared strip, called a blood glucose testing strip. The chemicals in the strip react with the blood, changing color according the concentration of glucose, which can then be read by comparing the color with a chart on the side of the test strip container.
- a blood glucose meter is an electronic device for measuring the blood glucose level. A relatively small drop of blood is placed on a disposable test strip which interfaces with a digital meter. Within several seconds, the level of blood glucose will be shown on the digital display. Sample sizes vary from 30 to 0.3 ⁇ l. Test times vary from 5 seconds to 2 minutes (modern meters are typically below 15 seconds)
- blood glucose meters seem a breakthrough in diabetes self care. As the drops of blood needed for the meter may be smaller, the pain associated with testing is reduced and the compliance of diabetic people to their testing regimens is improved. Although the cost of using blood glucose meters seems high; it is believed to be a cost benefit relative to the avoided medical costs of the complications of diabetes.
- a recent and welcome advantage is the use of small blood drops for blood glucose testing from other places than the finger tips.
- This alternate site testing uses the same test strips and meter, is practically pain free, and gives the finger tips a needed break if they become sore.
- a further improvement is provided by a continuous blood glucose monitor:
- a continuous blood glucose monitor determines blood glucose levels on a continuous basis (every few minutes).
- a typical system consists of:
- Continuous blood glucose monitors measure the glucose level of interstitial fluid. Continuous monitoring allows examination of how the blood glucose level reacts to insulin, exercise, food, and other factors. The additional data can be useful for setting correct insulin dosing ratios for food intake and correction of hyperglycemia. Monitoring during periods when blood glucose levels are not typically checked (e.g. overnight) can help to identify problems in insulin dosing (such as basal levels for insulin pump users or long-acting insulin levels for patients taking injections). Monitors may also be equipped with alarms to alert patients of hyperglycemia or hypoglycemia so that a patient can take corrective action(s) (after fingerstick testing, if necessary) even in cases where they do not feel symptoms of either condition.
- the present invention provides a biosensor comprising a hollow coil comprising wires coiled in parallel and an electronic circuit component operably connected to the coil, wherein the wires include at least a first coiled wire which may be used as a counter electrode, a second coiled wire which may be used as a working electrode and a third coiled wire which may be used as a reference electrode, wherein the second coiled wire is provided with a biocompatible layer comprising a bioreceptor, wherein the electronic circuit component is capable of generating an input signal for a transceiver based upon the activity of the bioreceptor and wirelessly sending the input signal to the transceiver and wherein the electronic circuit component is encapsulated in a biocompatible resin.
- the sensor according to the present invention has a generally cylindrical shape and essentially consists of two components: a hollow coil and an electronic circuit component attached to the coil.
- the electronic circuit component is connected to the coiled wires at its relevant points.
- the electronic circuit component is preferably attached at the end of the coil.
- the electronic circuit component may be placed inside the coil or outside the coil.
- the circuit component preferably extends in the axis direction of the coil so that the diameter of the sensor is not substantially increased by the circuit component protruding from the sensor in the radius direction.
- the diameter of the sensor is understood as the largest dimension of the sensor perpendicular to the axis direction of the coil.
- the sensor has a diameter of 0.1 to 3 mm.
- the sensor has a length of 5 to 20 mm.
- the length of the sensor is understood as the dimension of the total of the coil and the electronic circuit component in the axis direction of the coil.
- the term ‘hollow coil’ is understood to be an empty tubular body defined by one or more wires that loop around the circumference of the body, i.e. the wires are not wound around another electrode, a mandrel or other elements.
- the hollow coil is advantageous in that the sensor is flexible and can follow the shape of the surrounding environment in which the sensor is placed.
- the senor is placed in an aqueous environment containing a biomarker which interacts with the bioreceptor in the sensor.
- the aqueous environment may e.g. be the vascular system, the urinary tract, or other places in the body for instance intra-abdominal or intra-articular, intracapsular or intra-ocular.
- the sensor according to the invention can be worn under the upper or the lower eye lid in order to conveniently permit self monitoring of glucose levels in the lacrimal fluid and therewith give an indication of glucose levels in the blood.
- a sensor according to the invention suitable for use in this environment comprises glucose oxidase as the bioreceptor.
- the amount of H 2 O 2 generated is an indication of the amount of glucose in the tear liquid.
- a wireless transceiver which generates an electromagnetic field is placed close to the eye. The field powers the sensor inductively. The concentration of glucose is measured potentiometrically.
- the electronic circuit component generates an input signal indicating the amount of glucose present in the tear liquid and transmits the signal to the transceiver.
- the biocompatible layer prevents the bioreceptor from leaking or from being degraded by e.g. proteases present in the liquid environment.
- the biocompatible layer comprises the bioreceptor, i.e. the bioreceptor is immobilized in or on the biocompatible layer by being contained in, covered by or attached to the biocompatible layer.
- the biocompatible layer may be formed from a solution (e.g. buffer solution such as phosphate buffered saline) comprising a monomer and the bioreceptor, which is polymerized on the coil to be used as a working electrode.
- the biocompatible layer may also be formed by a standard dip coating process. The dip coating may be done in one step or in more than one step.
- the second coil is for example immersed in a solution comprising a polymer without the bioreceptor and then is subsequently immersed in a solution comprising a polymer and the bioreceptor.
- the second coil is immersed in an aqueous solution comprising the bioreceptor and then is subsequently immersed in a solution comprising a polymer for forming the biocompatible layer.
- the materials used for forming the biocompatible layer may render the biocompatible layer electroconductive or non-electroconductive.
- the solution for forming the biocompatible layer may comprise additives e.g. to enhance the solubility, to enhance uniformity of the coating formed or to increase the conductive property of the solution or the coating formed.
- a substituted dextran such as diethylaminoethyl-dextran (DEAE) has been shown to increase the stability of bioreceptors in the sensor.
- the additive for enhancing the conductive property include linear or cyclic aliphatic polyethers or polystyrenesulphonates.
- An example of surfactants includes polyethylene glycol (PEG).
- the circuit component is embedded in a biocompatible resin capping.
- the resin protects the circuit component from the external environment.
- examples of the resin include UV curable medical adhesives such as cyano acrylates, acrylated urethanes and silicones.
- the other end of the coil may also be provided with the resin capping.
- the second coiled wire is arranged to allow passing of electric current generated by the activity of the bioreceptor.
- One embodiment in which this is achieved is a sensor according to the invention wherein the second coiled wire has a Pt surface.
- This is advantageous in that a wide choice of materials is allowed for the coatings provided thereon.
- H 2 O 2 decomposes into water and oxygen on the platinum working electrode.
- the electrochemical decomposition is measured potentiometrically.
- a further embodiment in which this is achieved is a sensor according to the invention wherein the biocompatible layer comprising the bioreceptor is electroconductive.
- the electrons generated by the decomposition of H 2 O 2 are passed to the second coiled wire via the electroconductive layer in which the bioreceptor is present.
- the second coiled wire may be any electrode material for example those having a surface of Pt, Pd or an alloy thereof.
- the surface of the coiled wires may be made of a different material from the inside of the wires or the same material may be used for the surface and the inside of the coiled wires.
- the coiled wires may be made of stainless steel on which other metals such as Pt, Pd and Ag are coated.
- the coil is encapsulated in a top layer of a biocompatible material.
- the top layer encloses the coil when the coil is placed in a wet environment. This additional layer further increases the suitability of the use of the biosensor in a sensitive human body such as under the eyelid
- the biocompatible layer comprising the bioreceptor is electroconductive and the coil is encapsulated in a top layer of a biocompatible material.
- the second coiled wire has a Pt surface
- the biocompatible layer comprising the bioreceptor is electroconductive and the coil is encapsulated in a top layer of a biocompatible material
- the second coiled wire has a Pt surface, the biocompatible layer comprising the bioreceptor is electroconductive and the coil is not encapsulated in a top layer of a biocompatible material;
- the second coiled wire has a Pt surface, the biocompatible layer comprising the bioreceptor is not electroconductive and the coil is encapsulated in a top layer of a biocompatible material;
- the second coiled wire has a Pt surface, the biocompatible layer comprising the bioreceptor is not electroconductive and the coil is not encapsulated in a top layer of a biocompatible material;
- the second coiled wire has a surface made of a non-Pt metal, the biocompatible layer comprising the bioreceptor is electroconductive and the coil is encapsulated in a top layer of a biocompatible material and
- the second coiled wire has a surface made of a non-Pt metal, the biocompatible layer comprising the bioreceptor is electroconductive and the coil is not encapsulated in a top layer of a biocompatible material.
- only the coil may be encapsulated in the top layer or the sensor (the coil and the electronic circuit component) may be encapsulated in the top layer.
- the biocompatible material used for the top layer may be any known suitable material, as long as it is permeable to the biomarker that interacts with the bioreceptor in the sensor according to the present invention.
- the biocompatible material of the top layer is a hydrophilic material.
- the biocompatible material is a biocompatible hydrogel.
- the hydrogel is preferably a copolymer of a hydrophobic reactive monomer and a hydrophilic reactive monomer.
- Suitable examples may be the following combinations of hydrophilic and hydrophobic monomeric building blocks: (i) hydrophilic: N-vinylpyrrolidinone, hydrophobic: n-butylmetha-crylate; (ii), hydrophilic: hydroxyethylmethacrylate, hydrophobic: methylmethacrylate; (iii), hydrophilic: N-dimethylaminoethylmethacrylate, hydrophobic: cyclohexylacrylate.
- the hydrogel is a polysaccharide, for example those based on hyularon or chitosan and those based on synthetic polysaccharides such as cellulose ethylsulphonate or carboxymethylcellulose or mixtures thereof.
- the hydrogel is a block copolymer of polyethers differing by at least one carbon in the aliphatic region e.g. an ABA block co-polymer of polyethylene glycol and polypropylene glycol.
- the hydrogel is nafion (tetrafluoroethylene-perfluoro-3,6-dioxa-4-methyl-7-octenesulfonic acid copolymer).
- the electroconductive polymer in the biocompatible layer comprising the bioreceptor is preferably a polymer synthesised from an optionally substituted five-membered heterocycle of formula (I)
- Examples of substituted 5 membered heterocycles where the hetero atom is sulphur is 3,4-alkylenedioxythiophene.
- Preferred examples of 3,4-alkylenedioxythiophene include 2,3-dihydrothieno[3,4-b][1,4]dioxine 3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepine or 2,3,4,5-tetrahydrothieno[3,4-b][1,4]dioxocine.
- 3,4-alkylenedioxythiophene examples include 2,3-disubstituted-2,3-dihydrothieno[3,4-b][1,4]dioxine 2-substituted-2,3-dihydrothieno[3,4-b][1,4]dioxine 3-substituted-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepine 3,3-disubstituted-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepine 3,3-bis(substituted)-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepine or a 2,3,4,5-tetrasubstituted-2,3,4,5-tetrahydrothieno[3,4-b][1,4]dioxocine Particularly preferred are 2,3,4,5
- non-electroconductive material used for the biocompatible layer comprising the bioreceptor examples include 3,4-dihydroxy-L-phenylalanine (L-DOPA), chitosan, Nafion (tetrafluoroethylene-perfluoro-3,6-dioxa-4-methyl-7-octenesulfonic acid copolymer).
- L-DOPA 3,4-dihydroxy-L-phenylalanine
- Nafion tetrafluoroethylene-perfluoro-3,6-dioxa-4-methyl-7-octenesulfonic acid copolymer
- the third coiled wire is a silver/silver chloride reference electrode.
- the reference electrode may also function as an antenna by being connected to the relevant points of the electronic circuit component.
- the parallel wires of the sensor according to the present invention may further include a fourth coiled wire comprising an insulating layer which may be used as an antenna and/or a fifth coiled wire comprising an insulating layer which may be used as a spacer.
- the wires of the sensor according to the present invention may also include more than one of the further coiled wires which work as an antenna or a spacer.
- the insulating layer may e.g.
- parylene polytetrafluoro ethylene, fluorinated ethylene propylene, perfluroxalkoxy copolymer, polyphenylene sulfide, polyether block amide, Polyether ketone, poly amide, polyimide, polyesterimide, polyethylene such as high-density polyethylene and low-density polyethylene, polyvinylidene fluoride, or a polyurethane.
- the parallel wires of the sensor according to the present invention may include a further coiled wire provided with a biocompatible layer comprising a bioreceptor, which may be used as a further working electrode.
- the further coiled wire may have the same construction as the second coiled wire.
- the further coiled wire may also have a different construction from the second coiled wire, as long as it can work as a working electrode by suitable connection to the electronic circuit component.
- the bioreceptors on different working electrodes may be different.
- the coil of the sensor according to the present invention may also comprise more than one further coiled wire which work as a further working electrode.
- the bioreceptor in the sensor according to the present invention is preferably an oxidoreductase, i.e. a redox enzyme.
- the oxidoreductase of this type include EC1.1.3 (e.g. Glucose oxidase, L-gulonolactone oxidase, Thiamine oxidase, Xanthine oxidase), EC 1.3.3 (e.g. Protoporphyrinogen oxidase), EC 1.4.3 (e.g. Monoamine oxidase), EC 1.5.3 (e.g.
- Sarcosine oxidase Dihydrobenzophenanthridine oxidase
- EC 1.7.3 e.g. Urate oxidase
- EC 1.8.3 e.g. Sulfite oxidase
- EC 1.9.3 e.g. Cytochrome c oxidase
- EC 1.10.3 e.g. Catechol oxidase, Laccase
- EC 1.16.3 e.g. Ceruloplasmin
- the bioreceptor may preferably be chosen from the group consisting of glucose oxidase, lactate dehydrogenase, pyruvate dehyrrogenase and pyruvate oxidase.
- the present invention provides a medical device comprising the sensor according to the present invention and the transceiver.
- the present invention provides a process for making the sensor according to the present invention, comprising the steps of:
- the process further comprises the step of 4)
- the present invention provides use of the sensor according to the present invention or the medical device according to the present invention for the measurement of glucose levels in the eye.
- the present invention provides a method for diagnosing diabetes by using the sensor according to the present invention or the medical device according to the present invention.
- FIG. 1 schematically illustrates an embodiment of the sensor according to the invention
- FIG. 2 is a schematic diagram of an embodiment of the sensor according to the invention in which the details of the electronic circuit component are shown;
- FIG. 3 is a schematic diagram of a further embodiment of the sensor according to the invention in which the details of the electronic circuit component are shown;
- FIG. 4 illustrates the working principle of the potentiostat in the electronic circuit component in the sensor according to the present invention.
- FIGS. 5-8 illustrate various examples of the configuration of the biosensor according to the present invention.
- FIGS. 9-12 show various graphs obtained by experiments relating to the invention.
- FIG. 1 illustrates an embodiment of the sensor 100 according to the present invention.
- the sensor 100 comprises a hollow coil 10 comprising a first coiled wire 1 , a second coiled wire 2 , a third coiled wire 3 , a fourth coiled wire 4 and a fifth coiled wire 5 coiled in parallel.
- the hollow coil 10 is connected to an electronic circuit 20 .
- the electronic circuit 20 is attached at the end of the coil 10 .
- the hollow coil 10 in this example has a diameter of 1 mm.
- the first coiled wire 1 functions as a counter electrode.
- the second coiled wire 2 functions as a working electrode.
- the third coiled wire 3 functions as a reference electrode.
- the fourth coiled wire 4 functions as an antenna.
- the fifth coiled wire 5 functions as a spacer.
- the hollow coil 10 and the electronic circuit 20 are covered in a continuous top layer 11 .
- the electronic circuit 20 is embedded in a resin layer 21 under the top layer 11 .
- the first coiled wire 1 is made of a platinum-plated stainless steel and is provided only with the top layer 11 .
- the second coiled wire 2 is made of a platinum-plated stainless steel and is provided with a polymer layer 2 A under the top layer 11 .
- the polymer layer 2 A is electron conductive and comprises a bioreceptor 2 B, glucose oxidase in this example.
- the third coiled wire 3 is a silver plated stainless steel and is coated with a silver chloride layer 3 A under the top layer 11 .
- the fourth coiled wire 4 is made of a stainless steel and is coated with an insulating layer 4 A under the top layer 11 .
- the insulating layer 4 A is made of e.g. PTFE.
- the fifth coiled wire 5 is made of a stainless steel and is coated with an insulating layer 5 A under the top layer 11 .
- the insulating layer 5 A is made of e.g. PTFE.
- a return wire 22 for the antenna 4 extends from the electronic circuit component 2 to a different loop (not shown) of the fourth coiled wire 4 , so that a closed loop antenna is formed.
- the senor of this embodiment is placed in the lower eyelid filled with a tear fluid.
- Glucose in the tear liquid produces H 2 O 2 by the catalytic function of glucose oxidase in the polymer layer 2 A of the second coiled wire 2 .
- the sensor operates by an electromagnetic field generated by a transceiver (not shown) placed close to the lower eyelid.
- the electromagnetic field induces an electric current through the coil.
- the level of the electric current depends on the level of H 2 O 2 which in turn depends on the level of glucose in the tear liquid.
- the electronic circuit 20 generates a signal indicating the level of glucose and sends it to the external device through coil 4 .
- FIG. 2 schematically illustrates an embodiment of the sensor according to the invention.
- the electronic circuit 20 component is illustrated more in detail.
- the coil 10 comprises a coiled wire used as an antenna.
- the electronic circuit component 20 consists of a potentiostat 40 , a reference source 80 , an A/D converter 50 , a microprocessor 60 and a RF transceiver 70 .
- the potentiostat 40 translates the current of the working electrode into a voltage. This voltage is digitized by the A/D converter 50 into counts.
- the reference source 80 provides necessary bias voltages to the potentiostat 40 .
- the microprocessor 60 controls the processing of the sensor. The counts, i.e.
- the RF transceiver 70 is wirelessly connected to a reader unit (not shown here) using inductive coupling.
- the RF transceiver 70 is connected to the antenna coil by a return wire 30 .
- the RF transceiver 70 transmits the data packet containing the sensor raw data to the reader unit using the antenna coil.
- the sensor is wirelessly powered also using inductive coupling. For data and power transmission the same antenna coil is used.
- FIG. 3 schematically illustrates an embodiment of the electronic circuit component of the sensor according to the invention.
- FIG. 3 is identical to FIG. 2 except for that the antenna.
- the coil does not comprise a coiled wire used as an antenna.
- the electronic circuit component comprises an antenna for the data and power transmission.
- FIG. 4 illustrates the working principle of the potentiostat in the electronic circuit component in the sensor according to the present invention.
- the potentiostat consists of a differential input amplifier (OpAmp) and a transimpedance amplifier (TIA).
- the differential input amplifier compares the potential between the working (WE) and reference (RE) electrodes to adjust the required working bias potential.
- the voltage between the working and the reference electrodes may be amplified and applied to the counter electrode as an error signal.
- the transimpedance amplifier is connected to the working electrode and converts the cell current into a voltage (Out).
- the transimpedance amplifier keeps the potential of the working electrode at virtual ground.
- FIGS. 5-8 illustrate various examples of the configuration of the biosensor according to the present invention.
- the coil consists of four wires coiled in parallel.
- the wires are connected to the respective points of the electronic circuit component so that they respectively function as: counter electrode 1 , working electrode 2 , reference electrode 3 and antenna 4 .
- the coil consists of three wires coiled in parallel.
- the wires are connected to the respective points of the electronic circuit component so that they respectively function as: counter electrode 1 , working electrode 2 , reference electrode 3 ′.
- the wire which functions as a reference electrode also functions as an antenna.
- the coil consists of five wires coiled in parallel.
- the wires are connected to the respective points of the electronic circuit component so that they respectively function as: counter electrode 1 , working electrode 2 , reference electrode 3 , antenna 4 and spacer 5 .
- the coil consists of four wires coiled in parallel.
- the wires are connected to the respective points of the electronic circuit component so that they respectively function as: counter electrode 1 , working electrode 2 , reference electrode 3 ′ and spacer 5 .
- the wire which functions as a reference electrode 3 ′ also functions as an antenna.
- Example 1 Preparation of a Pt Working Electrode with an Electroconductive Layer of PEDOT, without a Top Layer (Non-Parallel Wires)
- An (enzyme) working electrode was prepared by dispersing 3,4-ethylenedioxythiophene (EDOT) ( ⁇ 10 ⁇ 2 M) in phosphate buffered saline (PBS), GOX ( ⁇ 110 U/mL) was added and was allowed to dissolve without agitation.
- EDOT 3,4-ethylenedioxythiophene
- PBS phosphate buffered saline
- GOX ⁇ 110 U/mL
- a three electrode electrochemical system was used whereby a platinum coiled wire (0.01 mm diameter) functions as the working electrode (WE), a platinum coiled wire functions as the counter electrode (CE) and a coiled Ag/AgCl/saturated KCl functions as the reference electrode (RE).
- WE working electrode
- CE counter electrode
- RE reference electrode
- the wires were not coiled in parallel, but existed as separate components.
- the electrodes formed an electrochemical cell for an electropolymerisation process.
- the WE was ultrasonically cleaned in ultra-pure water before use.
- the electrodes were placed in the EDOT/GOx/PBS solution and the potential was cycled between 0.2 and 1.2V/s for 15 cycles.
- the resulting coated electrode was washed with fresh PBS solution and could be used directly resulting in an immobilized GOx PEDOT matrix onto the platinum wire (Pt/PEDOT/GOx).
- a glucose calibration curve was made using the three electrode setup obtained by Example 1.
- Glucose PBS solutions from 0.00 to 0.40 mM with steps of 0.05 mM and from 0.50 to 8.00 mM with steps of 0.5 mM were prepared.
- Amperometry was performed for the different solutions.
- One potential step of 600 mV vs Ag/AgCl/saturated KCl was applied and the current was measured for 600 s, while the solution was stirred continuously.
- the average current and the standard deviation between 60 and 600 seconds was calculated and plotted against the glucose concentration.
- the current was linearly proportional to the glucose concentration in a range between 0 and 10 mM.
- the calibration curve produced for the low concentration range (0 to 0.7 mM) is shown in FIG. 9 . Symbols represent individual measurement points and the straight line represents the least squares fit to these points. Additional examples demonstrating the detection of glucose at hyperglycemic, physiological and hypoglycemic concentrations are shown in FIG. 10 .
- the region between 0 mM and 3.9 mM represents the hypoglycemic region
- the region between 3.9 mM and 5.5 mM represents the normal glucose region
- the region above 5.5 mM represents the hyperglycemic region.
- Example 3 Preparation of Pt Working Electrode with a Non-Electroconductive Layer of L-DOPA, without a Top Layer (Non-Parallel Wires)
- An (enzyme) working electrode was prepared by dissolving 3,4-dihydroxy-L-phenylalanine (L-DOPA) (20 mg) in 10 mL of a TRIS buffered solution (pH 7.5). A coiled platinum wire was immersed in this solution at room temperature for a period of 17 hours. The L-DOPA coated electrodes were subsequently immersed in a solution of PBS containing ⁇ 1000 U/mL of GOx for a period of 4.5 hours.
- L-DOPA 3,4-dihydroxy-L-phenylalanine
- Example 2 was repeated, but the working electrode was replaced by the electrode obtained by example 3. Calibration curves were produced showing that the measured current through the working electrode was substantially proportional to the glucose concentration.
- Example 5 Preparation of Pt Working Electrode with a Non-Electroconductive Layer of Chitosan, without a Top Layer (Non-Parallel Wires)
- An (enzyme) working electrode was prepared by, dissolving chitosan ( ⁇ 1 g) in 100 mL of 1% acetic acid. The solution was allowed to stand with stirring for a period of 3 hours at room temperature and then stored at 4° C. until required. To a solution of modified chitosan (3 mL) was added 15 ⁇ L poly(allylamine) (PAA) molecular weight ⁇ 65000 as a 20 wt % solution in H 2 O. Following complete dissolution of the PAA in the chitosan solution gluteraldehyde (60 ⁇ L) was added as a 25 wt % solution in H 2 O. This solution is subsequently termed solution 1.
- PAA poly(allylamine)
- Example 5 Representative amperometry measurements were carried out by combining the working electrode obtained by Example 5 with a platinum coiled wire counter electrode and a coiled wire Ag/AgCl reference electrode. The coated electrodes were stored in PBS at 4° C. until required.
- the measured current through the working electrode was substantially proportional to the glucose concentration.
- Example 7 Preparation of Pt Working Electrode with a Non-Electroconductive Layer of Nafion, without a Top Layer (Non-Parallel Wires)
- An (enzyme) working electrode was prepared by dissolving GOx (2.7 mg) and bovine serum albumin (BSA) in a solution of PBS (1 mM) containing PEG (615 mg). On full dissolution of the GOx and BSA a solution of gluteraldehyde (15 ⁇ L of 2.5 wt % in H 2 O) was added and the solution was mixed thoroughly. A platinum coiled wire (diameter 0.1 mm) was polished with silica and cleaned in a H 2 SO 4 /H 2 O 2 solution (1:3) and rinsed with ultrapure water. The Gox solution (2 ⁇ L) was drop cast onto the surface of the cleaned platinum wire and allowed to dry at room temperature for 1 hour.
- BSA bovine serum albumin
- Nafion tetrafluoroethylene-perfluoro-3,6-dioxa-4-methyl-7-octenesulfonic acid copolymer
- Example 2 was repeated, but the working electrode was replaced by the electrode obtained by example 7. Calibration curves were produced showing that the measured current through the working electrode was substantially proportional to the glucose concentration.
- Example 9 Preparation of a Pt Working Electrode with an Electroconductive Layer of PEDOT without a Top Layer (Non-Parallel Wires)
- An (enzyme) working electrode was prepared by, dispersing 3,4-ethylenedioxythiophene (EDOT) (0.01M) in phosphate buffered saline (PBS) containing PEG8000 (0.001M). To the EDOT solution was added GOx (5312.7 U) which was allowed to dissolve without agitation.
- EDOT 3,4-ethylenedioxythiophene
- a three-electrode electrochemical system was used: consisting of coiled working electrode (WE), diameter 1.5 mm, a coiled platinum wire as counter electrode (CE) and a Ag/AgCl/saturated KCl reference electrode (RE).
- WE coiled working electrode
- CE counter electrode
- RE Ag/AgCl/saturated KCl reference electrode
- the WE was precleaned by sequential washing in H 2 SO 4 , ultrapure water and finally in PBS.
- the electrodes were placed in the EDOT/GOx/PEG/PBS solution and the potential was cycled from 0.3V between 0.2-1.2 V at a scan rate of 0.1 V/s for 30 cycles.
- Example 2 was repeated, but the working electrode was replaced by the electrode obtained by example 9. Calibration curves were produced showing that the measured current through the working electrode was substantially proportional to the glucose concentration, as shown in FIG. 12 .
- Examples 1-10 are repeated, except that the wires used as the WE, CE and RE are coiled in parallel. No substantial difference is noted in the sensing behavior between the examples wherein the wires not coiled in parallel are used (Examples 1-10) and the examples wherein the wires coiled in parallel are used (Example 11).
- Example 12 Parallel Wires with a Top Layer
- Examples 1-10 are repeated, except that the wires used as the WE, CE and RE are coiled in parallel and the coil is dip coated with a solution of Nafion (tetrafluoroethylene-perfluoro-3,6-dioxa-4-methyl-7-octenesulfonic acid copolymer) (10 wt % in water) and allowed to dry at room temperature. A coil encapsulated in Nafion is obtained. No substantial difference is noted in the sensing behavior between Examples 11 and 12.
- Nafion tetrafluoroethylene-perfluoro-3,6-dioxa-4-methyl-7-octenesulfonic acid copolymer
- Example 13 Preparation of a Pt Working Electrode with an Electroconductive Layer of PEDOT (Parallel Wires)
- a wire of platinum plated stainless steel, diameter 0.152 mm may be coated with a copolymer of BMA and NVP.
- Another wire of platinum plated stainless steel, diameter 0.152 mm may be coated electrochemically with PEDOT/GOx which again may be coated with the copolymer of BMA and NVP.
- a silver plated stainless steel wire, diameter 0.152 mm may be coated with a silverchloride layer which may also be coated with the copolymer.
- These three wires may be coiled in parallel around a mandrel. The formed coil then have an outer diameter of 0.87 mm. After removal of the mandrel the coil may be cut into pieces of 1 cm in length. One of the ends of the coil may be closed with a drop of UV-curable polymer. The three wires at the other end of the coil may then be connected to an electronic circuit.
- Calibration curves are produced according to the procedure similar to Example 2.
- the measured current through the working electrode is substantially proportional to the glucose concentration.
- the coil made according to the examples 1-13 is connected to an electronic circuit component to form the biosensor.
- the electronic signal obtained from the sensor may be transmitted by an antenna system and received by an external device, for example mounted in a pair of glasses. This may in turn amplify the signal and transmit it to another device, for example an insulin pump.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Heart & Thoracic Surgery (AREA)
- Electrochemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Polymers & Plastics (AREA)
- Composite Materials (AREA)
Abstract
Description
- The invention relates to a biosensor and to a process for the preparation thereof. The invention also relates to a medical device comprising the biosensor.
- Blood glucose monitoring is a way of testing the concentration of glucose in the blood (glycemia). It is important in the care of diabetes mellitus.
- A blood glucose test is generally performed by piercing the skin (typically, on the finger tip) to draw blood, then placing the blood on a chemically active disposable strip which indicates the result either by changing colour, or changing an electrical characteristic, the latter being measured by an electronic meter.
- Most people with
Type 2 diabetes test at least once per day (usually before breakfast) to assess the effectiveness of their diet and exercise. - Many people with
Type 2 diabetes use an oral medication to combat their insulin resistance, and test their blood glucose before and after breakfast to assess the effectiveness of their dosage. Diabetics who use insulin (allType 1 diabetes patients andmany Type 2 diabetes patients) usually test their blood sugar more often, such as 3 to 10 times per day, both to assess the effectiveness of their prior insulin dose and to help determining the time of their next insulin dose. - Improved technology for measuring blood glucose is rapidly changing the standards of care for all diabetic people. There are several methods of blood glucose testing currently available.
- Chemical Test Strips: Chemical test strips are a medium cost method for monitoring blood glucose. A fairly large drop of blood, usually taken from the fingertip, is placed on a chemically prepared strip, called a blood glucose testing strip. The chemicals in the strip react with the blood, changing color according the concentration of glucose, which can then be read by comparing the color with a chart on the side of the test strip container.
- Blood Glucose Meters: A blood glucose meter is an electronic device for measuring the blood glucose level. A relatively small drop of blood is placed on a disposable test strip which interfaces with a digital meter. Within several seconds, the level of blood glucose will be shown on the digital display. Sample sizes vary from 30 to 0.3 μl. Test times vary from 5 seconds to 2 minutes (modern meters are typically below 15 seconds)
- Although more expensive, blood glucose meters seem a breakthrough in diabetes self care. As the drops of blood needed for the meter may be smaller, the pain associated with testing is reduced and the compliance of diabetic people to their testing regimens is improved. Although the cost of using blood glucose meters seems high; it is believed to be a cost benefit relative to the avoided medical costs of the complications of diabetes.
- A recent and welcome advantage is the use of small blood drops for blood glucose testing from other places than the finger tips. This alternate site testing uses the same test strips and meter, is practically pain free, and gives the finger tips a needed break if they become sore.
- A further improvement is provided by a continuous blood glucose monitor: A continuous blood glucose monitor (CGM) determines blood glucose levels on a continuous basis (every few minutes). A typical system consists of:
- a) disposable glucose biosensor placed just under the skin, which is worn for a few days until replacement;
- b) a link from the sensor to a non-implanted transmitter which communicates to a radio receiver;
- c) an electronic receiver worn like a pager (or insulin pump) that displays blood glucose levels on a practically continuous manner, as well as monitors rising and falling trends in glycemic excursions.
- Continuous blood glucose monitors measure the glucose level of interstitial fluid. Continuous monitoring allows examination of how the blood glucose level reacts to insulin, exercise, food, and other factors. The additional data can be useful for setting correct insulin dosing ratios for food intake and correction of hyperglycemia. Monitoring during periods when blood glucose levels are not typically checked (e.g. overnight) can help to identify problems in insulin dosing (such as basal levels for insulin pump users or long-acting insulin levels for patients taking injections). Monitors may also be equipped with alarms to alert patients of hyperglycemia or hypoglycemia so that a patient can take corrective action(s) (after fingerstick testing, if necessary) even in cases where they do not feel symptoms of either condition.
- Studies have demonstrated that patients with continuous sensors experience less hyperglycemia and also reduce their glycosylated hemoglobin levels. This technology is an important component in the effort to develop a closed-loop system connecting real-time automatic control of an insulin pump based on immediate blood glucose data from the sensor.
- It is a goal of the present invention to provide a more reliable, cheap and easy-to-use biosensor, preferably a continuous monitoring biosensor, and more preferably a bio-implant continuous monitoring biosensor. Accordingly, the present invention provides a biosensor comprising a hollow coil comprising wires coiled in parallel and an electronic circuit component operably connected to the coil, wherein the wires include at least a first coiled wire which may be used as a counter electrode, a second coiled wire which may be used as a working electrode and a third coiled wire which may be used as a reference electrode, wherein the second coiled wire is provided with a biocompatible layer comprising a bioreceptor, wherein the electronic circuit component is capable of generating an input signal for a transceiver based upon the activity of the bioreceptor and wirelessly sending the input signal to the transceiver and wherein the electronic circuit component is encapsulated in a biocompatible resin.
- The sensor according to the present invention has a generally cylindrical shape and essentially consists of two components: a hollow coil and an electronic circuit component attached to the coil. The electronic circuit component is connected to the coiled wires at its relevant points. The electronic circuit component is preferably attached at the end of the coil. The electronic circuit component may be placed inside the coil or outside the coil. In the cases where the circuit component is placed outside the coil, the circuit component preferably extends in the axis direction of the coil so that the diameter of the sensor is not substantially increased by the circuit component protruding from the sensor in the radius direction. As used herein, the diameter of the sensor is understood as the largest dimension of the sensor perpendicular to the axis direction of the coil. Preferably, the sensor has a diameter of 0.1 to 3 mm. Preferably, the sensor has a length of 5 to 20 mm. As used herein, the length of the sensor is understood as the dimension of the total of the coil and the electronic circuit component in the axis direction of the coil.
- As used herein, the term ‘hollow coil’ is understood to be an empty tubular body defined by one or more wires that loop around the circumference of the body, i.e. the wires are not wound around another electrode, a mandrel or other elements.
- The hollow coil is advantageous in that the sensor is flexible and can follow the shape of the surrounding environment in which the sensor is placed.
- During use, the sensor is placed in an aqueous environment containing a biomarker which interacts with the bioreceptor in the sensor. The aqueous environment may e.g. be the vascular system, the urinary tract, or other places in the body for instance intra-abdominal or intra-articular, intracapsular or intra-ocular. In particular, the sensor according to the invention can be worn under the upper or the lower eye lid in order to conveniently permit self monitoring of glucose levels in the lacrimal fluid and therewith give an indication of glucose levels in the blood. A sensor according to the invention suitable for use in this environment comprises glucose oxidase as the bioreceptor.
- Glucose Oxidase Catalyzes the Following Reaction:
- The amount of H2O2 generated is an indication of the amount of glucose in the tear liquid. For operation of the sensor, a wireless transceiver which generates an electromagnetic field is placed close to the eye. The field powers the sensor inductively. The concentration of glucose is measured potentiometrically. The electronic circuit component generates an input signal indicating the amount of glucose present in the tear liquid and transmits the signal to the transceiver.
- The electronic circuit component capable of such actions is known per se and examples of such electronic circuit component is described elsewhere in the description referring to figures. More details of examples of such electronic circuit components can be found in DE 10 2007 038 402, DE 10 2008 049 648 A1 and
EP 1 475 886 B1. - The biocompatible layer prevents the bioreceptor from leaking or from being degraded by e.g. proteases present in the liquid environment.
- The biocompatible layer comprises the bioreceptor, i.e. the bioreceptor is immobilized in or on the biocompatible layer by being contained in, covered by or attached to the biocompatible layer. The biocompatible layer may be formed from a solution (e.g. buffer solution such as phosphate buffered saline) comprising a monomer and the bioreceptor, which is polymerized on the coil to be used as a working electrode. The biocompatible layer may also be formed by a standard dip coating process. The dip coating may be done in one step or in more than one step. When this is done in two steps, the second coil is for example immersed in a solution comprising a polymer without the bioreceptor and then is subsequently immersed in a solution comprising a polymer and the bioreceptor. In another example of a two step dip coating process, the second coil is immersed in an aqueous solution comprising the bioreceptor and then is subsequently immersed in a solution comprising a polymer for forming the biocompatible layer.
- The materials used for forming the biocompatible layer may render the biocompatible layer electroconductive or non-electroconductive. The solution for forming the biocompatible layer may comprise additives e.g. to enhance the solubility, to enhance uniformity of the coating formed or to increase the conductive property of the solution or the coating formed. For example, a substituted dextran such as diethylaminoethyl-dextran (DEAE) has been shown to increase the stability of bioreceptors in the sensor. Examples of the additive for enhancing the conductive property include linear or cyclic aliphatic polyethers or polystyrenesulphonates. An example of surfactants includes polyethylene glycol (PEG).
- The circuit component is embedded in a biocompatible resin capping. The resin protects the circuit component from the external environment. Examples of the resin include UV curable medical adhesives such as cyano acrylates, acrylated urethanes and silicones. The other end of the coil may also be provided with the resin capping.
- The second coiled wire is arranged to allow passing of electric current generated by the activity of the bioreceptor.
- One embodiment in which this is achieved is a sensor according to the invention wherein the second coiled wire has a Pt surface. This is advantageous in that a wide choice of materials is allowed for the coatings provided thereon. H2O2 decomposes into water and oxygen on the platinum working electrode. The electrochemical decomposition is measured potentiometrically.
- A further embodiment in which this is achieved is a sensor according to the invention wherein the biocompatible layer comprising the bioreceptor is electroconductive. The electrons generated by the decomposition of H2O2 are passed to the second coiled wire via the electroconductive layer in which the bioreceptor is present. In this case, the second coiled wire may be any electrode material for example those having a surface of Pt, Pd or an alloy thereof.
- The surface of the coiled wires may be made of a different material from the inside of the wires or the same material may be used for the surface and the inside of the coiled wires. For example, the coiled wires may be made of stainless steel on which other metals such as Pt, Pd and Ag are coated.
- Preferably, the coil is encapsulated in a top layer of a biocompatible material. The top layer encloses the coil when the coil is placed in a wet environment. This additional layer further increases the suitability of the use of the biosensor in a sensitive human body such as under the eyelid
- In preferred embodiments, the biocompatible layer comprising the bioreceptor is electroconductive and the coil is encapsulated in a top layer of a biocompatible material.
- The following specific embodiments of the sensor according to the present invention are mentioned:
- the second coiled wire has a Pt surface, the biocompatible layer comprising the bioreceptor is electroconductive and the coil is encapsulated in a top layer of a biocompatible material;
- the second coiled wire has a Pt surface, the biocompatible layer comprising the bioreceptor is electroconductive and the coil is not encapsulated in a top layer of a biocompatible material;
- the second coiled wire has a Pt surface, the biocompatible layer comprising the bioreceptor is not electroconductive and the coil is encapsulated in a top layer of a biocompatible material;
- the second coiled wire has a Pt surface, the biocompatible layer comprising the bioreceptor is not electroconductive and the coil is not encapsulated in a top layer of a biocompatible material;
- the second coiled wire has a surface made of a non-Pt metal, the biocompatible layer comprising the bioreceptor is electroconductive and the coil is encapsulated in a top layer of a biocompatible material and
- the second coiled wire has a surface made of a non-Pt metal, the biocompatible layer comprising the bioreceptor is electroconductive and the coil is not encapsulated in a top layer of a biocompatible material.
- According to the present invention, only the coil may be encapsulated in the top layer or the sensor (the coil and the electronic circuit component) may be encapsulated in the top layer.
- The biocompatible material used for the top layer may be any known suitable material, as long as it is permeable to the biomarker that interacts with the bioreceptor in the sensor according to the present invention.
- Preferably, the biocompatible material of the top layer is a hydrophilic material. Preferably, the biocompatible material is a biocompatible hydrogel.
- In some embodiments, the hydrogel is preferably a copolymer of a hydrophobic reactive monomer and a hydrophilic reactive monomer. Suitable examples may be the following combinations of hydrophilic and hydrophobic monomeric building blocks: (i) hydrophilic: N-vinylpyrrolidinone, hydrophobic: n-butylmetha-crylate; (ii), hydrophilic: hydroxyethylmethacrylate, hydrophobic: methylmethacrylate; (iii), hydrophilic: N-dimethylaminoethylmethacrylate, hydrophobic: cyclohexylacrylate.
- In some embodiments, the hydrogel is a polysaccharide, for example those based on hyularon or chitosan and those based on synthetic polysaccharides such as cellulose ethylsulphonate or carboxymethylcellulose or mixtures thereof.
- In some embodiments, the hydrogel is a block copolymer of polyethers differing by at least one carbon in the aliphatic region e.g. an ABA block co-polymer of polyethylene glycol and polypropylene glycol.
- In some embodiments, the hydrogel is nafion (tetrafluoroethylene-perfluoro-3,6-dioxa-4-methyl-7-octenesulfonic acid copolymer).
- The electroconductive polymer in the biocompatible layer comprising the bioreceptor is preferably a polymer synthesised from an optionally substituted five-membered heterocycle of formula (I)
-
- wherein R1 stands for a hetero atom, preferably N, S or O,
- wherein R2, R3 are each independently selected from the group of H, optionally substituted alkyl of preferably 1 to 4 C atoms, wherein the alkyl may be substituted with for example a hydroxyl group, alkyl group and alkyl ether, optionally substituted o-alkyl, and wherein R2 and R3 may form a ring together with the carbon atoms to which they are connected.
- Examples of substituted 5 membered heterocycles where the hetero atom is sulphur is 3,4-alkylenedioxythiophene. Preferred examples of 3,4-alkylenedioxythiophene include 2,3-dihydrothieno[3,4-b][1,4]
dioxine 3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepine or 2,3,4,5-tetrahydrothieno[3,4-b][1,4]dioxocine. Other preferred examples of 3,4-alkylenedioxythiophene include 2,3-disubstituted-2,3-dihydrothieno[3,4-b][1,4]dioxine 2-substituted-2,3-dihydrothieno[3,4-b][1,4]dioxine 3-substituted-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepine 3,3-disubstituted-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepine 3,3-bis(substituted)-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepine or a 2,3,4,5-tetrasubstituted-2,3,4,5-tetrahydrothieno[3,4-b][1,4]dioxocine Particularly preferred are 2,3-dimethyl-2,3-dihydrothieno[3,4-b][1,4]dioxine 3,3-dimethyl-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepine 3,3-bis(methoxymethyl)-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepine 2,3,4,5-tetramethyl-2,3,4,5-tetrahydrothieno[3,4-b][1,4]dioxocine 2,3-dihydrothieno[3,4-b][1,4]dioxin-2-ol 2-methyl-2,3-dihydrothieno[3,4-b][1,4]dioxine 2,3-dihydrothieno[3,4-b][1,4]dioxin-2-ylmethanol 2-phenyl-2,3-dihydrothieno[3,4-b][1,4]dioxine Sodium 4-(2,3-dihydrothieno[3,4-b][1,4]dioxin-2-ylmethoxy)butane-1-sulfonate 3-methyl-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepine 3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepin-3-ylmethanol 3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepin-3-ol 5,10-dihydrothieno[3,4-c][2,5]benzodioxocine or 2-methyl-2,3-dihydrothieno[3,4-b][1,4]dioxine. Most preferred monomer is the unsubstituted 3,4-ethylenedioxythiophene. - Examples of the non-electroconductive material used for the biocompatible layer comprising the bioreceptor include 3,4-dihydroxy-L-phenylalanine (L-DOPA), chitosan, Nafion (tetrafluoroethylene-perfluoro-3,6-dioxa-4-methyl-7-octenesulfonic acid copolymer).
- Preferably, the third coiled wire is a silver/silver chloride reference electrode. The reference electrode may also function as an antenna by being connected to the relevant points of the electronic circuit component.
- The parallel wires of the sensor according to the present invention may further include a fourth coiled wire comprising an insulating layer which may be used as an antenna and/or a fifth coiled wire comprising an insulating layer which may be used as a spacer. The wires of the sensor according to the present invention may also include more than one of the further coiled wires which work as an antenna or a spacer. The insulating layer may e.g. be made of parylene, polytetrafluoro ethylene, fluorinated ethylene propylene, perfluroxalkoxy copolymer, polyphenylene sulfide, polyether block amide, Polyether ketone, poly amide, polyimide, polyesterimide, polyethylene such as high-density polyethylene and low-density polyethylene, polyvinylidene fluoride, or a polyurethane.
- The parallel wires of the sensor according to the present invention may include a further coiled wire provided with a biocompatible layer comprising a bioreceptor, which may be used as a further working electrode. The further coiled wire may have the same construction as the second coiled wire. The further coiled wire may also have a different construction from the second coiled wire, as long as it can work as a working electrode by suitable connection to the electronic circuit component. In particular, the bioreceptors on different working electrodes may be different. The coil of the sensor according to the present invention may also comprise more than one further coiled wire which work as a further working electrode.
- The bioreceptor in the sensor according to the present invention is preferably an oxidoreductase, i.e. a redox enzyme. Preferably, the bioreceptor is an oxidoreductase of the enzyme commission groups EC 1.X.3 where X=1-17. Examples of the oxidoreductase of this type include EC1.1.3 (e.g. Glucose oxidase, L-gulonolactone oxidase, Thiamine oxidase, Xanthine oxidase), EC 1.3.3 (e.g. Protoporphyrinogen oxidase), EC 1.4.3 (e.g. Monoamine oxidase), EC 1.5.3 (e.g. Sarcosine oxidase, Dihydrobenzophenanthridine oxidase), EC 1.7.3 (e.g. Urate oxidase), EC 1.8.3 (e.g. Sulfite oxidase), EC 1.9.3 (e.g. Cytochrome c oxidase), EC 1.10.3 (e.g. Catechol oxidase, Laccase) and EC 1.16.3 (e.g. Ceruloplasmin).
- The bioreceptor may preferably be chosen from the group consisting of glucose oxidase, lactate dehydrogenase, pyruvate dehyrrogenase and pyruvate oxidase.
- According to a further aspect of the present invention, the present invention provides a medical device comprising the sensor according to the present invention and the transceiver.
- According to a further aspect of the present invention, the present invention provides a process for making the sensor according to the present invention, comprising the steps of:
-
- 1) providing the hollow coil,
- 2) connecting the coil with the electric circuit component and
- 3) encapsulating the electric circuit component with a biocompatible resin.
- Preferably, the process further comprises the step of 4)
- providing the top layer on the coil or on the coil and the electric circuit component after step 3).
- According to a further aspect of the present invention, the present invention provides use of the sensor according to the present invention or the medical device according to the present invention for the measurement of glucose levels in the eye.
- According to a further aspect of the present invention, the present invention provides a method for diagnosing diabetes by using the sensor according to the present invention or the medical device according to the present invention.
- The invention will be described in detail below referring to the drawings in which:
-
FIG. 1 schematically illustrates an embodiment of the sensor according to the invention; -
FIG. 2 is a schematic diagram of an embodiment of the sensor according to the invention in which the details of the electronic circuit component are shown; -
FIG. 3 is a schematic diagram of a further embodiment of the sensor according to the invention in which the details of the electronic circuit component are shown; -
FIG. 4 illustrates the working principle of the potentiostat in the electronic circuit component in the sensor according to the present invention. -
FIGS. 5-8 illustrate various examples of the configuration of the biosensor according to the present invention. -
FIGS. 9-12 show various graphs obtained by experiments relating to the invention. -
FIG. 1 illustrates an embodiment of thesensor 100 according to the present invention. Thesensor 100 comprises ahollow coil 10 comprising a firstcoiled wire 1, a secondcoiled wire 2, a thirdcoiled wire 3, a fourthcoiled wire 4 and a fifthcoiled wire 5 coiled in parallel. Thehollow coil 10 is connected to anelectronic circuit 20. Theelectronic circuit 20 is attached at the end of thecoil 10. Thehollow coil 10 in this example has a diameter of 1 mm. - The first
coiled wire 1 functions as a counter electrode. The secondcoiled wire 2 functions as a working electrode. The thirdcoiled wire 3 functions as a reference electrode. The fourthcoiled wire 4 functions as an antenna. The fifthcoiled wire 5 functions as a spacer. - The
hollow coil 10 and theelectronic circuit 20 are covered in a continuoustop layer 11. Theelectronic circuit 20 is embedded in aresin layer 21 under thetop layer 11. - The first
coiled wire 1 is made of a platinum-plated stainless steel and is provided only with thetop layer 11. - The second
coiled wire 2 is made of a platinum-plated stainless steel and is provided with apolymer layer 2A under thetop layer 11. Thepolymer layer 2A is electron conductive and comprises abioreceptor 2B, glucose oxidase in this example. - The third
coiled wire 3 is a silver plated stainless steel and is coated with asilver chloride layer 3A under thetop layer 11. - The fourth
coiled wire 4 is made of a stainless steel and is coated with an insulatinglayer 4A under thetop layer 11. The insulatinglayer 4A is made of e.g. PTFE. - The fifth
coiled wire 5 is made of a stainless steel and is coated with an insulatinglayer 5A under thetop layer 11. The insulatinglayer 5A is made of e.g. PTFE. - A return wire 22 for the
antenna 4 extends from theelectronic circuit component 2 to a different loop (not shown) of the fourthcoiled wire 4, so that a closed loop antenna is formed. - During use, the sensor of this embodiment is placed in the lower eyelid filled with a tear fluid. Glucose in the tear liquid produces H2O2 by the catalytic function of glucose oxidase in the
polymer layer 2A of the secondcoiled wire 2. - The sensor operates by an electromagnetic field generated by a transceiver (not shown) placed close to the lower eyelid. The electromagnetic field induces an electric current through the coil. The level of the electric current depends on the level of H2O2 which in turn depends on the level of glucose in the tear liquid. The
electronic circuit 20 generates a signal indicating the level of glucose and sends it to the external device throughcoil 4. -
FIG. 2 schematically illustrates an embodiment of the sensor according to the invention. Theelectronic circuit 20 component is illustrated more in detail. In this example, thecoil 10 comprises a coiled wire used as an antenna. Theelectronic circuit component 20 consists of apotentiostat 40, areference source 80, an A/D converter 50, amicroprocessor 60 and aRF transceiver 70. Thepotentiostat 40 translates the current of the working electrode into a voltage. This voltage is digitized by the A/D converter 50 into counts. Thereference source 80 provides necessary bias voltages to thepotentiostat 40. Themicroprocessor 60 controls the processing of the sensor. The counts, i.e. the sensor raw data, are converted into a transmit data packet, for example as described in the Norm ISO 18000-3, by themicroprocessor 60. TheRF transceiver 70 is wirelessly connected to a reader unit (not shown here) using inductive coupling. TheRF transceiver 70 is connected to the antenna coil by areturn wire 30. TheRF transceiver 70 transmits the data packet containing the sensor raw data to the reader unit using the antenna coil. The sensor is wirelessly powered also using inductive coupling. For data and power transmission the same antenna coil is used. -
FIG. 3 schematically illustrates an embodiment of the electronic circuit component of the sensor according to the invention.FIG. 3 is identical toFIG. 2 except for that the antenna. In this example, the coil does not comprise a coiled wire used as an antenna. Instead, the electronic circuit component comprises an antenna for the data and power transmission. -
FIG. 4 illustrates the working principle of the potentiostat in the electronic circuit component in the sensor according to the present invention. The potentiostat consists of a differential input amplifier (OpAmp) and a transimpedance amplifier (TIA). The differential input amplifier compares the potential between the working (WE) and reference (RE) electrodes to adjust the required working bias potential. For this purpose, the voltage between the working and the reference electrodes may be amplified and applied to the counter electrode as an error signal. Thus the voltage between working and reference electrodes is maintained to be constant. The transimpedance amplifier is connected to the working electrode and converts the cell current into a voltage (Out). The transimpedance amplifier keeps the potential of the working electrode at virtual ground. -
FIGS. 5-8 illustrate various examples of the configuration of the biosensor according to the present invention. - In
FIG. 5 , the coil consists of four wires coiled in parallel. The wires are connected to the respective points of the electronic circuit component so that they respectively function as:counter electrode 1, workingelectrode 2,reference electrode 3 andantenna 4. - In
FIG. 6 , the coil consists of three wires coiled in parallel. The wires are connected to the respective points of the electronic circuit component so that they respectively function as:counter electrode 1, workingelectrode 2,reference electrode 3′. In this embodiment, the wire which functions as a reference electrode also functions as an antenna. - In
FIG. 7 , the coil consists of five wires coiled in parallel. The wires are connected to the respective points of the electronic circuit component so that they respectively function as:counter electrode 1, workingelectrode 2,reference electrode 3,antenna 4 andspacer 5. - In
FIG. 8 , the coil consists of four wires coiled in parallel. The wires are connected to the respective points of the electronic circuit component so that they respectively function as:counter electrode 1, workingelectrode 2,reference electrode 3′ andspacer 5. In this embodiment, the wire which functions as areference electrode 3′ also functions as an antenna. - An (enzyme) working electrode was prepared by dispersing 3,4-ethylenedioxythiophene (EDOT) (˜10−2 M) in phosphate buffered saline (PBS), GOX (˜110 U/mL) was added and was allowed to dissolve without agitation.
- A three electrode electrochemical system was used whereby a platinum coiled wire (0.01 mm diameter) functions as the working electrode (WE), a platinum coiled wire functions as the counter electrode (CE) and a coiled Ag/AgCl/saturated KCl functions as the reference electrode (RE). The wires were not coiled in parallel, but existed as separate components. The electrodes formed an electrochemical cell for an electropolymerisation process.
- The WE was ultrasonically cleaned in ultra-pure water before use. The electrodes were placed in the EDOT/GOx/PBS solution and the potential was cycled between 0.2 and 1.2V/s for 15 cycles. The resulting coated electrode was washed with fresh PBS solution and could be used directly resulting in an immobilized GOx PEDOT matrix onto the platinum wire (Pt/PEDOT/GOx).
- A glucose calibration curve was made using the three electrode setup obtained by Example 1.
- Glucose PBS solutions from 0.00 to 0.40 mM with steps of 0.05 mM and from 0.50 to 8.00 mM with steps of 0.5 mM were prepared.
- Amperometry was performed for the different solutions. One potential step of 600 mV vs Ag/AgCl/saturated KCl was applied and the current was measured for 600 s, while the solution was stirred continuously. The average current and the standard deviation between 60 and 600 seconds was calculated and plotted against the glucose concentration.
- It was observed that the current was linearly proportional to the glucose concentration in a range between 0 and 10 mM. The calibration curve produced for the low concentration range (0 to 0.7 mM) is shown in
FIG. 9 . Symbols represent individual measurement points and the straight line represents the least squares fit to these points. Additional examples demonstrating the detection of glucose at hyperglycemic, physiological and hypoglycemic concentrations are shown inFIG. 10 . The region between 0 mM and 3.9 mM represents the hypoglycemic region, the region between 3.9 mM and 5.5 mM represents the normal glucose region and the region above 5.5 mM represents the hyperglycemic region. - An (enzyme) working electrode was prepared by dissolving 3,4-dihydroxy-L-phenylalanine (L-DOPA) (20 mg) in 10 mL of a TRIS buffered solution (pH 7.5). A coiled platinum wire was immersed in this solution at room temperature for a period of 17 hours. The L-DOPA coated electrodes were subsequently immersed in a solution of PBS containing ˜1000 U/mL of GOx for a period of 4.5 hours.
- A coiled platinum wire coated with a non-conductive coating of L-DOPA comprising GOx was thus obtained.
- Example 2 was repeated, but the working electrode was replaced by the electrode obtained by example 3. Calibration curves were produced showing that the measured current through the working electrode was substantially proportional to the glucose concentration.
- An (enzyme) working electrode was prepared by, dissolving chitosan (˜1 g) in 100 mL of 1% acetic acid. The solution was allowed to stand with stirring for a period of 3 hours at room temperature and then stored at 4° C. until required. To a solution of modified chitosan (3 mL) was added 15 μL poly(allylamine) (PAA) molecular weight ˜65000 as a 20 wt % solution in H2O. Following complete dissolution of the PAA in the chitosan solution gluteraldehyde (60 μL) was added as a 25 wt % solution in H2O. This solution is subsequently termed
solution 1. Into a separate solution of modified chitosan (3 mL) was added GOx (˜7 mg) after full dissolution of the GOx in the chitosan solution gluteraldehyde (60 μL) was added as a 25 wt % solution in H2O. This solution is subsequently termedsolution 2. A platinum coil cleaned using a mixture of H2SO4 and H2O2 rinsed with ultrapure water and further cleaned in an ultrasonic bath containing ultrapure water. The cleaned platinum coil was dip coated withsolution 1 and allowed to dry for 2 hours at room temperature before being dipcoated withsolution 2 and allowed to dry. - A coiled platinum wire coated with a non-conductive coating of chitosan comprising GOx was thus obtained.
- Representative amperometry measurements were carried out by combining the working electrode obtained by Example 5 with a platinum coiled wire counter electrode and a coiled wire Ag/AgCl reference electrode. The coated electrodes were stored in PBS at 4° C. until required.
- Calibration curves were produced according to the procedure similar to Example 2. The calibration curves produced using this electrode are shown in
FIG. 11 . The graph on the left represents the current dependence on glucose concentration onday 1 and the graph on left shows the current dependence on glucose concentration onday 2 andday 3. - The measured current through the working electrode was substantially proportional to the glucose concentration.
- An (enzyme) working electrode was prepared by dissolving GOx (2.7 mg) and bovine serum albumin (BSA) in a solution of PBS (1 mM) containing PEG (615 mg). On full dissolution of the GOx and BSA a solution of gluteraldehyde (15 μL of 2.5 wt % in H2O) was added and the solution was mixed thoroughly. A platinum coiled wire (diameter 0.1 mm) was polished with silica and cleaned in a H2SO4/H2O2 solution (1:3) and rinsed with ultrapure water. The Gox solution (2 μL) was drop cast onto the surface of the cleaned platinum wire and allowed to dry at room temperature for 1 hour. Following drying a solution of Nafion (tetrafluoroethylene-perfluoro-3,6-dioxa-4-methyl-7-octenesulfonic acid copolymer) (10 wt % in water) was placed on the surface and allowed to dry for 1 hour at room temperature.
- A coiled platinum wire coated with a non-conductive coating of Nafion comprising GOx was thus obtained.
- Example 2 was repeated, but the working electrode was replaced by the electrode obtained by example 7. Calibration curves were produced showing that the measured current through the working electrode was substantially proportional to the glucose concentration.
- An (enzyme) working electrode was prepared by, dispersing 3,4-ethylenedioxythiophene (EDOT) (0.01M) in phosphate buffered saline (PBS) containing PEG8000 (0.001M). To the EDOT solution was added GOx (5312.7 U) which was allowed to dissolve without agitation.
- A three-electrode electrochemical system was used: consisting of coiled working electrode (WE), diameter 1.5 mm, a coiled platinum wire as counter electrode (CE) and a Ag/AgCl/saturated KCl reference electrode (RE). The electrodes formed an electrochemical cell for an electropolymerisation process.
- The WE was precleaned by sequential washing in H2SO4, ultrapure water and finally in PBS. The electrodes were placed in the EDOT/GOx/PEG/PBS solution and the potential was cycled from 0.3V between 0.2-1.2 V at a scan rate of 0.1 V/s for 30 cycles.
- A coiled platinum wire coated with a conductive coating of PEDOT comprising GOx was thus obtained.
- Example 2 was repeated, but the working electrode was replaced by the electrode obtained by example 9. Calibration curves were produced showing that the measured current through the working electrode was substantially proportional to the glucose concentration, as shown in
FIG. 12 . - Examples 1-10 are repeated, except that the wires used as the WE, CE and RE are coiled in parallel. No substantial difference is noted in the sensing behavior between the examples wherein the wires not coiled in parallel are used (Examples 1-10) and the examples wherein the wires coiled in parallel are used (Example 11).
- Examples 1-10 are repeated, except that the wires used as the WE, CE and RE are coiled in parallel and the coil is dip coated with a solution of Nafion (tetrafluoroethylene-perfluoro-3,6-dioxa-4-methyl-7-octenesulfonic acid copolymer) (10 wt % in water) and allowed to dry at room temperature. A coil encapsulated in Nafion is obtained. No substantial difference is noted in the sensing behavior between Examples 11 and 12.
- A wire of platinum plated stainless steel, diameter 0.152 mm, may be coated with a copolymer of BMA and NVP. Another wire of platinum plated stainless steel, diameter 0.152 mm, may be coated electrochemically with PEDOT/GOx which again may be coated with the copolymer of BMA and NVP. A silver plated stainless steel wire, diameter 0.152 mm, may be coated with a silverchloride layer which may also be coated with the copolymer. These three wires may be coiled in parallel around a mandrel. The formed coil then have an outer diameter of 0.87 mm. After removal of the mandrel the coil may be cut into pieces of 1 cm in length. One of the ends of the coil may be closed with a drop of UV-curable polymer. The three wires at the other end of the coil may then be connected to an electronic circuit.
- Calibration curves are produced according to the procedure similar to Example 2. The measured current through the working electrode is substantially proportional to the glucose concentration.
- The coil made according to the examples 1-13 is connected to an electronic circuit component to form the biosensor. The electronic signal obtained from the sensor may be transmitted by an antenna system and received by an external device, for example mounted in a pair of glasses. This may in turn amplify the signal and transmit it to another device, for example an insulin pump.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/822,710 US20200223876A1 (en) | 2011-04-18 | 2020-03-18 | Biosensor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161517415P | 2011-04-18 | 2011-04-18 | |
PCT/EP2012/057040 WO2012143370A2 (en) | 2011-04-18 | 2012-04-18 | Biosensor |
US201314112095A | 2013-11-20 | 2013-11-20 | |
US16/822,710 US20200223876A1 (en) | 2011-04-18 | 2020-03-18 | Biosensor |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/112,095 Continuation US10631769B2 (en) | 2011-04-18 | 2012-04-18 | Biosensor |
PCT/EP2012/057040 Continuation WO2012143370A2 (en) | 2011-04-18 | 2012-04-18 | Biosensor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200223876A1 true US20200223876A1 (en) | 2020-07-16 |
Family
ID=46022191
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/112,095 Active 2035-02-26 US10631769B2 (en) | 2011-04-18 | 2012-04-18 | Biosensor |
US16/822,710 Abandoned US20200223876A1 (en) | 2011-04-18 | 2020-03-18 | Biosensor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/112,095 Active 2035-02-26 US10631769B2 (en) | 2011-04-18 | 2012-04-18 | Biosensor |
Country Status (7)
Country | Link |
---|---|
US (2) | US10631769B2 (en) |
EP (1) | EP2699690B1 (en) |
JP (1) | JP6046115B2 (en) |
KR (1) | KR101952468B1 (en) |
CN (1) | CN103687958B (en) |
BR (1) | BR112013026733A2 (en) |
WO (1) | WO2012143370A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9788765B2 (en) | 2012-09-28 | 2017-10-17 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
US20140209481A1 (en) * | 2013-01-25 | 2014-07-31 | Google Inc. | Standby Biasing Of Electrochemical Sensor To Reduce Sensor Stabilization Time During Measurement |
US8922366B1 (en) * | 2013-06-28 | 2014-12-30 | Google Inc. | Reader communication with contact lens sensors and display device |
US9459201B2 (en) | 2014-09-29 | 2016-10-04 | Zyomed Corp. | Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing |
CN105361891A (en) * | 2015-10-19 | 2016-03-02 | 中国农业大学 | Blood glucose sensor planted in live fish eye ball sclera interstitial fluid and production method of blood glucose sensor |
EP4253536A3 (en) | 2015-12-30 | 2023-12-20 | DexCom, Inc. | Diffusion resistance layer for analyte sensors |
US9554738B1 (en) | 2016-03-30 | 2017-01-31 | Zyomed Corp. | Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing |
WO2018185313A1 (en) | 2017-04-07 | 2018-10-11 | Noviosense B.V. | Coating for implantable medical device |
US11382540B2 (en) | 2017-10-24 | 2022-07-12 | Dexcom, Inc. | Pre-connected analyte sensors |
JP2021520900A (en) | 2018-04-10 | 2021-08-26 | リ・ガリ・ベスローテン・フエンノートシャップLi Galli B.V. | Measurement of the vagina using a vaginal ring |
KR20210088979A (en) | 2020-01-07 | 2021-07-15 | 엘지이노텍 주식회사 | Sensing device |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4703756A (en) * | 1986-05-06 | 1987-11-03 | The Regents Of The University Of California | Complete glucose monitoring system with an implantable, telemetered sensor module |
US5593852A (en) * | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
US6544193B2 (en) * | 1996-09-04 | 2003-04-08 | Marcio Marc Abreu | Noninvasive measurement of chemical substances |
US6175752B1 (en) * | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US6515144B2 (en) * | 2001-05-22 | 2003-02-04 | The Board Of Regents Of The University Of Nebraska | Oligothiophenes and synthesis thereof |
WO2002097416A1 (en) * | 2001-05-30 | 2002-12-05 | I-Sens, Inc. | Biosensor |
EP1475886B1 (en) | 2003-05-06 | 2006-12-20 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Apparatus having resonant circuit adjustable for minimum power consumption of an amplifier |
WO2007120442A2 (en) * | 2003-07-25 | 2007-10-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7125382B2 (en) * | 2004-05-20 | 2006-10-24 | Digital Angel Corporation | Embedded bio-sensor system |
DE102004033288A1 (en) * | 2004-07-09 | 2006-02-02 | H.C. Starck Gmbh | New 3,4-alkylenedioxythiophene compounds comprising five membered heterocyclic terminal groups, repeating units of five membered heterocyclic compounds and terminal groups useful to prepare electrically conductive oligo- or polymers |
WO2006127694A2 (en) * | 2004-07-13 | 2006-11-30 | Dexcom, Inc. | Analyte sensor |
EP2054476B9 (en) * | 2006-07-25 | 2012-03-14 | Glumetrics, Inc. | Flourescent dyes for use in glucose sensing |
US7747318B2 (en) * | 2006-12-07 | 2010-06-29 | Neuropace, Inc. | Functional ferrule |
EP2111148B1 (en) * | 2007-01-19 | 2015-08-12 | Given Imaging (Los Angeles) LLC | Micro-remote gastrointestinal physiological measurement device |
DE102007038402A1 (en) | 2007-05-31 | 2008-12-24 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Device and method for detecting a pressure-dependent parameter |
GB0715590D0 (en) * | 2007-08-09 | 2007-09-19 | Glysure Ltd | Sensing apparatus |
US8663105B2 (en) * | 2008-08-11 | 2014-03-04 | Nxp, B.V. | Ingestible devices for measuring physiological parameters |
DE102008049648A1 (en) | 2008-09-30 | 2010-04-15 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Rectifier arrangement for use in transponder, has compensation circuit supplying compensation voltage to control port such that current flow is provided between sink and source connections of transistor |
WO2010056624A2 (en) * | 2008-11-11 | 2010-05-20 | Isense Corporation | Long-term implantable biosensor |
-
2012
- 2012-04-18 JP JP2014505595A patent/JP6046115B2/en not_active Expired - Fee Related
- 2012-04-18 EP EP12717642.8A patent/EP2699690B1/en not_active Not-in-force
- 2012-04-18 BR BR112013026733A patent/BR112013026733A2/en not_active Application Discontinuation
- 2012-04-18 CN CN201280018965.2A patent/CN103687958B/en not_active Expired - Fee Related
- 2012-04-18 KR KR1020137030507A patent/KR101952468B1/en active IP Right Grant
- 2012-04-18 US US14/112,095 patent/US10631769B2/en active Active
- 2012-04-18 WO PCT/EP2012/057040 patent/WO2012143370A2/en active Application Filing
-
2020
- 2020-03-18 US US16/822,710 patent/US20200223876A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
Li, Chunyan, Jungyoup Han, and Chong H. Ahn. "Flexible biosensors on spirally rolled micro tube for cardiovascular in vivo monitoring." Biosensors and Bioelectronics 22.9-10 (2007): 1988-1993. (Year: 2007) * |
Also Published As
Publication number | Publication date |
---|---|
WO2012143370A2 (en) | 2012-10-26 |
US10631769B2 (en) | 2020-04-28 |
EP2699690A2 (en) | 2014-02-26 |
CN103687958A (en) | 2014-03-26 |
BR112013026733A2 (en) | 2016-09-06 |
JP6046115B2 (en) | 2016-12-14 |
KR20140067973A (en) | 2014-06-05 |
KR101952468B1 (en) | 2019-02-26 |
JP2014516628A (en) | 2014-07-17 |
WO2012143370A3 (en) | 2012-12-27 |
CN103687958B (en) | 2015-11-25 |
US20140081105A1 (en) | 2014-03-20 |
EP2699690B1 (en) | 2014-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200223876A1 (en) | Biosensor | |
US9755390B2 (en) | Process for making biosensor | |
US8116840B2 (en) | Method of calibrating of an analyte-measurement device, and associated methods, devices and systems | |
KR100771711B1 (en) | Glucose biosensor | |
KR102044061B1 (en) | Continuous glucose monitoring apparatus, continuous glucose monitoring system comprising said apparatus and method using said system | |
US20120283542A1 (en) | Correlation of Alternative Site Blood and Interstitial Fluid Glucose Concentrations to Venous Glucose Concentration | |
JP5711141B2 (en) | Substrate concentration continuous measurement method | |
WO2014004460A1 (en) | Use of sensor redundancy to detect sensor failures | |
Chen et al. | Recent advances of tissue-interfaced chemical biosensors | |
EP4225140A1 (en) | In-vivo glucose specific sensor | |
US20210386331A1 (en) | Methods, systems, and devices for improved sensors for continuous glucose monitoring | |
Hanssen et al. | Biosensor | |
Meshram et al. | A Real Time GSM Based Embedded System for Blood Glucose Level Monitoring and Messaging | |
Dawji | Implantable Gluocose Monitoring Systems–A |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NOVIOSENSE B.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HANSSEN, JOHANNES HENDRIKUS LEONARDUS;TWEEHUYSEN, ROBERT;REEL/FRAME:052154/0926 Effective date: 20131016 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: WMC GROUP LLC, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVIOSENSE B.V.;REEL/FRAME:058843/0285 Effective date: 20211215 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |